Toll Free: 1-888-928-9744

Global Non-small Cell Lung Cancer Market 2014-2018

Sep 10, 2014 | 92 Pages | Technavio | Healthcare

About Non-small Cell Lung Cancer
Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.
TechNavio's analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 3.62 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Non-small Cell Lung Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through various therapies adopted for the treatment of non-small cell lung cancer, including
 Biologics
 Small Molecules
TechNavio's report, the Global Non-small Cell Lung Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Non-small Cell Lung Cancer market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
 Americas 
 APAC
 EMEA        
Key Vendors
 AstraZeneca
 Celgene
 Eli Lilly
 F. Hoffmann-La Roche 
 Pfizer
Other Prominent Vendors
 
 Aetna
 Boehringer Ingelheim
 Celldex
 Eisai
 GlaxoSmithKline
 IMClone
 Merck Serono
 Novartis
 Qiagen
 OncoGenex
 OSI Pharmaceuticals
 Pierre Fabre
 Sanofi
 Synta
Market Driver
 High Unmet Needs
 For a full, detailed list, view our report
Market Challenge
 High Cost of Therapy
 For a full, detailed list, view our report
Market Trend
 Availability of Personalized Medicine
 For a full, detailed list, view our report
Key Questions Answered in this Report
 What will the market size be in 2018 and what will the growth rate be?
 What are the key market trends?
 What is driving this market?
 What are the challenges to market growth?
 Who are the key vendors in this market space?
 What are the market opportunities and threats faced by the key vendors?
 What are the strengths and weaknesses of the key vendors?
 
Table of Contents

01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 03.1 Market Overview 03.2 Product Offerings 04. Product Profiles 04.1.1 Iressa 04.1.2 Abraxane 04.1.3 Alimta 04.1.4 Gemzar 04.1.5 Xalkori 04.1.6 Avastin 04.1.7 Tarceva 05. Market Research Methodology 05.1 Market Research Process 05.2 Research Methodology 06. Introduction 07. Market Landscape 07.1 Market Overview 07.2 Market Size and Forecast 07.3 Five Forces Analysis 08. Market Segmentation by Molecule Type 08.1 Biologics 08.2 Small Molecules 09. Market Segmentation by Route of Administration 09.1 Oral 09.2 Parenteral 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 18.1 Competitive Scenario 18.1.1 Key News 18.1.2 Mergers and Acquisitions 18.2 Market Share Analysis 2013 18.3 AstraZeneca 18.3.1 Iressa 18.4 Celgene 18.4.1 Abraxane 18.5 Eli Lilly 18.5.1 Alimta 18.5.2 Gemzar 18.6 Pfizer 18.6.1 Xalkori 18.7 Roche 18.7.1 Avastin 18.7.2 Tarceva 18.8 Other Prominent Vendors 19. Pipeline Portfolio 20. Key Vendor Analysis 20.1 AstraZeneca plc 20.1.1 Key Facts 20.1.2 Business Description 20.1.3 Business Segmentation 20.1.4 Business Strategy 20.1.5 Revenue by Business Segmentation 20.1.6 Revenue Comparison 2011-2013 20.1.7 Sales Revenue by Geographical Segmentation 20.1.8 Key Developments 20.1.9 SWOT Analysis 20.2 Celgene 20.2.1 Key Facts 20.2.2 Business Description 20.2.3 Business Strategy 20.2.4 Business Segmentation by Revenue 2011-2013 20.2.5 Sales by Geography 20.2.6 Key Developments 20.2.7 SWOT Analysis 20.3 Eli Lilly 20.3.1 Key Facts 20.3.2 Business Overview 20.3.3 Business Segmentation by Revenue 2013 20.3.4 Business Segmentation by Revenue 2012 and 2013 20.3.5 Sales by Geography 20.3.6 Business Strategy 20.3.7 Key Developments 20.3.8 SWOT Analysis 20.4 Pfizer 20.4.1 Key Facts 20.4.2 Business Description 20.4.3 Business Segmentation 20.4.4 Revenue by Business Segmentation 20.4.5 Revenue Comparison 2012 and 2013 20.4.6 Sales by Geography 20.4.7 Business Strategy 20.4.8 Key Developments 20.4.9 SWOT Analysis 20.5 Roche 20.5.1 Key Facts 20.5.2 Business Overview 20.5.3 Business Segmentation by Revenue 2013 20.5.4 Business Segmentation by Revenue 2012 and 2013 20.5.5 Geographical Segmentation by Revenue 2013 20.5.6 Business Strategy 20.5.7 Recent Developments 20.5.8 SWOT Analysis 21. Other Reports in this Series
List of Exhibits: Exhibit 1: Market Research Methodology Exhibit 2: Global Non-Small-Cell Lung Cancer Market 2013-2018 (US$ billion) Exhibit 3: Global Non-Small-Cell Lung Cancer Market Segmentation by Molecule Type Exhibit 4: Global Non-Small-Cell Lung Cancer Market Segmentation by Molecule Type 2013 Exhibit 5: Global Non-Small-Cell Lung Cancer Market Segmentation by Route of Administration Exhibit 6: Global Non-Small-Cell Lung Cancer Market Segmentation by Route of Administration 2013 Exhibit 7: Global Non-Small-Cell Lung Cancer Market by Geographical Segmentation 2013 Exhibit 8: Global Non-Small-Cell Lung Cancer Market Share Analysis 2013 Exhibit 9: Sales Comparison of Major Drugs 2010-2013 (US$ million) Exhibit 10: AstraZeneca's Iressa Sales Comparison 2006-2013 (US$ million) Exhibit 11: Iressa Sales Comparison in Western Europe 2009-2013 (US$ million) Exhibit 12: Iressa Sales Comparison in the Established ROW 2009-2013 (US$ million) Exhibit 13: Iressa Sales Comparison in the Emerging Markets 2009-2013 (US$ million) Exhibit 14: Region-wise Total Sales Comparison of Iressa 2009-2011 (US$ million) Exhibit 15: Sales Comparison of Abraxane 2009-2013 (in US$ million) Exhibit 16: Sales Comparison of Alimta 2003-2011 in the US (US$ million) Exhibit 17: Sales Comparison of Alimta 2003-2011 Outside the US (US$ million) Exhibit 18: Total Sales Comparison of Alimta 2003-2011 (US$ million) Exhibit 19: Region-wise Total Sales Comparison of Alimta 2003-2011 (US$ million) Exhibit 20: Sales Comparison of Gemzar in the US 2003-2011 (US$ million) Exhibit 21: Sales Comparison of Gemzar Outside the US 2003-2011 (US$ million) Exhibit 22: Worldwide Total Sales Comparison of Gemzar 2003-2011 (US$ million) Exhibit 23: Region-wise Total Sales Comparison of Gemzar 2003-2011 (US$ million) Exhibit 24: Sales Forecast of Xalkori 2013-2018 (US$ million) Exhibit 25: Sales Comparison of Avastin and Tarceva 2005-2013 (in US$ million) Exhibit 26: Sales Comparison of Avastin 2005-2013 (US$ million) Exhibit 27: Sales Comparison of Tarceva 2005-2013 (US$ million) Exhibit 28: Late Stage Pipeline Molecules for Non-Small-Cell-Lung Cancer Exhibit 29: AstraZeneca plc: Business Segmentation Exhibit 30: AstraZeneca plc: Revenue by Business Segmentation2013 Exhibit 31: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion) Exhibit 32: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013 Exhibit 33: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million) Exhibit 34: Celgene Corp.: Sales by Geography 2013 Exhibit 35: Eli Lilly and Co.: Business Segmentation by Revenue 2013 Exhibit 36: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million) Exhibit 37: Eli Lilly and Co.: Sales by Geography 2013 Exhibit 38: Pfizer Inc.: Business Segmentation Exhibit 39: Pfizer Inc.: Revenue by Business Segmentation 2013 Exhibit 40: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013 Exhibit 41: Pfizer Inc.: Revenue by Geography 2013 Exhibit 42: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013 Exhibit 43: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 Exhibit 44: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division) Exhibit 45: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)

To request a sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...October 15, 2015

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...October 12, 2015

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...October 21, 2015

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...October 21, 2015

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...October 30, 2015
Choose License Type
Single User - US$ 2500.00
Multi User - US$ 3500.00
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify